Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.8 SEK | +2.15% | -1.30% | +41.26% |
Mar. 13 | CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries | CI |
Feb. 21 | Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI). | CI |
Sales 2021 | 91.15M 8.43M | Sales 2022 | 28.73M 2.66M | Capitalization | 181M 16.73M |
---|---|---|---|---|---|
Net income 2021 | 21M 1.94M | Net income 2022 | -6M -555K | EV / Sales 2021 | 0.98 x |
Net cash position 2021 | 137M 12.65M | Net cash position 2022 | 132M 12.19M | EV / Sales 2022 | 1.71 x |
P/E ratio 2021 |
9.42
x | P/E ratio 2022 |
-29.4
x | Employees | 11 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 69.54% |
1 day | +2.15% | ||
1 week | -1.30% | ||
Current month | +6.44% | ||
1 month | -0.52% | ||
3 months | +23.58% | ||
6 months | +53.54% | ||
Current year | +41.26% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Ekolind
CEO | Chief Executive Officer | 60 | 22-09-26 |
Louise Aspenberg
DFI | Director of Finance/CFO | 48 | 20-10-11 |
Daniela Morath
ADM | Chief Administrative Officer | 44 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gunilla Lundmark
BRD | Director/Board Member | 61 | 20-12-31 |
Director/Board Member | 59 | 19-12-31 | |
Director/Board Member | 54 | 14-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 3.8 | +2.15% | 9 353 |
24-04-22 | 3.72 | -3.38% | 6,237 |
24-04-19 | 3.85 | 0.00% | 39,034 |
24-04-18 | 3.85 | 0.00% | 2,408 |
24-04-17 | 3.85 | 0.00% | 31,934 |
Delayed Quote Nasdaq Stockholm, April 23, 2024 at 11:04 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+41.26% | 6.75M | |
-0.41% | 103B | |
+3.55% | 96.73B | |
+1.66% | 21.31B | |
-16.16% | 21.21B | |
-6.82% | 18.79B | |
-41.41% | 16.37B | |
-23.30% | 13.68B | |
+5.78% | 13.44B | |
+22.70% | 10.98B |
- Stock Market
- Equities
- COMBI Stock